Fulgent Announces ASCO Rapid Oral Abstract Showing 60% ORR, 7.2‑mo mPFS for FID-007 plus Cetuximab
Fulgent (FLGT) reported positive interim Phase 2 data for its drug FID-007 combined with cetuximab, showing a 60% objective response rate and a median progression-free survival of 7.2 months. These findings will be presented at the ASCO Rapid Oral session on June 1, 2026. The company noted a favorable safety profile with mostly grade 1–2 treatment-related adverse events.
Fulgent (NASDAQ: FLGT) reports 60% ORR in Phase 2 FID-007 cancer trial
Fulgent Genetics announced positive interim Phase 2 results for its cancer drug candidate FID-007 in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The study showed an objective response rate of 60% and a median progression-free survival of 7.2 months in 42 efficacy-evaluable patients. The company highlights these results as significantly better than historical standards of care, with a favorable safety profile noted, although overall survival data is still immature.
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
Fulgent Genetics, Inc. announced the full abstract publication for its drug FID-007, which will be presented at the ASCO 2026 Annual Meeting in the Head and Neck Cancer Track. Interim Phase 2 study data show FID-007, combined with cetuximab, demonstrates meaningful clinical activity and a favorable safety profile in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), with an objective response rate of 60%. This new treatment option shows potential for a patient population where current therapies have limited efficacy.
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT) following a reported decline in revenue and a significant impact from a transitioning major customer. The firm is focusing on whether Fulgent's executive officers complied with federal securities laws and is encouraging affected shareholders to join their investigation to potentially recover losses.
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT) to determine if investor losses can be recovered under federal securities laws. The investigation follows Fulgent's disclosure of lower-than-anticipated 2025 revenue and decreased fourth-quarter revenue, primarily due to reduced volume from its largest customer transitioning testing in-house. Shareholders who suffered losses are encouraged to contact Johnson Fistel for more information.
Fulgent Genetics (FLGT) director receives stock units and 8,426-share option grant
Fulgent Genetics director Michael Nohaile reported new equity awards, including 5,558 shares of common stock and options for 8,426 shares with an exercise price of $16.19. Both the restricted stock units and options vest over a four-year period, contingent on his continued service to the company. These awards are compensation-related grants, not open-market transactions, and bring Nohaile's direct holdings to 24,578 shares.
Fulgent Genetics (NASDAQ: FLGT) director receives 11,117 RSUs
Fulgent Genetics (NASDAQ: FLGT) director Linda Dong was granted 11,117 Restricted Stock Units (RSUs) with a grant price of $0.00, increasing her direct holdings to 38,758 shares. These RSUs will vest over four years, with a quarter vesting after 12 months (May 14, 2026) and the remainder quarterly over the next three years, contingent on her continued service. The transaction was reported in a Form 4 filing and is considered compensation rather than an open-market purchase.
Fulgent Genetics (NASDAQ: FLGT) director awarded 11,117 restricted stock units
Fulgent Genetics director Regina E. Groves was granted 11,117 restricted stock units (RSUs) of common stock, increasing her direct holdings to 28,099 shares. These RSUs were awarded at no cash cost and will vest over a four-year period, with the first quarter vesting after 12 months and the rest quarterly over the subsequent 36 months, conditional on her continued service. The transaction was reported via a Form 4 filing with the SEC.
Fulgent Genetics (FLGT) price target decreased by 28.85% to 18.87
This article reports a significant decrease in the price target for Fulgent Genetics (FLGT). The target has been lowered by 28.85% to $18.87. Further details regarding the reasons for this adjustment are not provided in the snippet.
Fulgent Genetics (FLGT) price target decreased by 28.85% to 18.87
This article reports a significant decrease in the price target for Fulgent Genetics (FLGT). The target has been lowered by 28.85% to $18.87. This adjustment reflects an anticipated dip in the stock's valuation.
Fulgent Genetics Shareholders Approve New 2026 Equity Plan
Fulgent Genetics shareholders approved a new 2026 Equity Incentive Plan on May 14, 2026, which replaces a previous plan and authorizes up to 2,000,000 new shares plus additional shares from forfeited awards, aiming to impact employee incentives and potential shareholder dilution. Concurrently, shareholders re-elected four directors, ratified Deloitte & Touche LLP as the independent auditor, and approved executive compensation. Despite current financial losses, the company maintains a strong balance sheet and anticipates H2 2026 growth, with recovery in profitability remaining a key risk.
Fulgent Genetics (NASDAQ: FLGT) wins stockholder approval for 2026 equity plan
Fulgent Genetics (NASDAQ: FLGT) stockholders approved the 2026 Equity Incentive Plan, authorizing 2,000,000 new common shares and up to 1,500,000 additional shares from forfeited awards under the previous plan. The company also elected four directors, ratified Deloitte & Touche LLP as its independent auditor, and approved executive compensation on an advisory basis. These actions were taken during the 2026 annual meeting where approximately 83% of eligible shares were present.
ETFs Investing in Fulgent Genetics, Inc. Stocks
This article lists various ETFs that include Fulgent Genetics, Inc. (7F0 on the Stuttgart Stock Exchange) in their holdings. The ETFs are sorted by the market value of their Fulgent Genetics, Inc. stock holdings and provide key metrics like market value, weight, issuer, management style, expense ratio, AUM, price, change, related volume, and 3-year NAV total return. The information aims to help investors identify funds with exposure to Fulgent Genetics, offering diversified investment opportunities.
Fulgent Genetics infertility test panels broaden to cover over 140 genes for females and 160 for males
Fulgent Genetics has significantly expanded its infertility next-generation sequencing (NGS) panels, now covering 143 genes for females and 163 genes for males. The company recommends combining these expanded panels with BeaconCarrierScreening for a thorough reproductive health assessment. This enhancement aims to provide more comprehensive genetic insights for couples facing fertility challenges.
LA500 2026: Ming Hsieh
Ming Hsieh, Chairman and CEO of Fulgent Genetics, is featured in the LA500 2026 list. Hsieh founded Fulgent Genetics in 2011 to offer affordable genetic testing, and the company significantly expanded into COVID-19 testing during the pandemic, generating substantial revenue. Despite a recent decline in revenue after a major customer took genetic testing in-house, Fulgent Genetics is leveraging its past testing revenue to re-establish a drug development division, currently engaged in clinical trials for a squamous cell carcinoma drug.
Fulgent Genetics (NasdaqGM:FLGT) Stock Forecast & Analyst Predictions
Fulgent Genetics (FLGT) is forecast to grow earnings by 5% and revenue by 11.2% per annum, though it is expected to remain unprofitable for the next three years. Analyst price targets have seen adjustments, with reductions due to lower multiple assumptions and increases due to improved profitability outlooks. The company is actively expanding its capabilities through strategic partnerships, such as with Foundation Medicine for pharmacogenetic testing, and continues to provide updated earnings guidance.
Fulgent Genetics (NASDAQ:FLGT) Stock Passes Below Fifty Day Moving Average - Here's Why
Fulgent Genetics (NASDAQ:FLGT) shares have fallen below their 50-day moving average, trading as low as $14.94, while analysts have become more cautious, with Piper Sandler cutting its price target. Although the company beat EPS expectations in its latest quarter, revenue was slightly below estimates, and it anticipates continued losses for the current fiscal year. Institutional investors have recently adjusted their positions in the stock.
Fulgent Genetics (NASDAQ:FLGT) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded Fulgent Genetics (NASDAQ:FLGT) from "sell" to "strong sell," reflecting a cautious sentiment among analysts, with a consensus "Hold" rating and an average price target of $27.00. Other firms like Piper Sandler and Zacks Research have also issued more conservative ratings. Despite beating EPS expectations in its latest quarter, the company reported slightly lower revenue and continues to face negative profitability metrics and weak forward earnings guidance.
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
Lowey Dannenberg P.C. is investigating Fulgent Genetics, Inc. (NASDAQ: FLGT) for potential violations of federal securities laws. This investigation follows Fulgent's report of fourth-quarter revenue decline and full-year 2025 revenue that slightly missed updated guidance. The firm encourages investors who suffered losses to contact them regarding the investigation.
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics
Lowey Dannenberg, P.C. is investigating Fulgent Genetics, Inc. (NASDAQ: FLGT) for potential violations of federal securities laws. This investigation follows Fulgent's Q4 and full-year 2025 financial results, which showed that full-year revenue slightly missed updated guidance and fourth-quarter revenue declined sequentially. The law firm encourages investors who suffered losses to contact them regarding the investigation.
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
Lowey Dannenberg P.C. is investigating Fulgent Genetics, Inc. (NASDAQ: FLGT) for potential violations of federal securities laws. This investigation follows Fulgent's announcement of its fourth quarter and full-year 2025 financial results, where the company's full-year 2025 revenue of approximately $322.7 million fell slightly below its updated guidance and fourth-quarter revenue declined sequentially. The firm encourages investors who suffered losses in Fulgent securities to contact their attorneys to discuss the investigation.
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics
Lowey Dannenberg, P.C. is investigating Fulgent Genetics, Inc. (NASDAQ: FLGT) for potential violations of federal securities laws. This investigation follows Fulgent's fourth quarter and full-year 2025 financial results, which showed that full-year revenue of $322.7 million slightly missed updated guidance and fourth-quarter revenue declined sequentially. Investors who suffered losses are encouraged to contact the firm.
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
Lowey Dannenberg P.C. is investigating Fulgent Genetics, Inc. (NASDAQ: FLGT) for potential violations of federal securities laws after the company reported disappointing financial results for the fourth quarter and full year 2025. Fulgent's 2025 revenue of approximately $322.7 million fell slightly short of updated guidance, and fourth-quarter revenue declined sequentially. The firm encourages investors who suffered losses to contact their attorneys for more information regarding the investigation.
Number of shareholders of Fulgent Genetics, Inc. – NASDAQ:FLGT
The article provides a title indicating it will discuss the number of shareholders for Fulgent Genetics, Inc. (NASDAQ:FLGT). However, the actual content only contains navigation links, legal disclaimers, and various product/community links related to TradingView, without presenting any specific shareholder data. It states that market data is provided by ICE Data Services and reference data by FactSet.
New cancer drug-gene test targets adverse reaction risk
Foundation Medicine and Fulgent Genetics are expanding their partnership to launch FoundationOne® PGx, a pharmacogenetic offering designed to identify genetic differences influencing how cancer medicines are metabolized. This new solution aims to guide cancer therapy selection and dosing strategies, thereby reducing the risk of adverse drug reactions and improving treatment effectiveness. The offering will be available in the United States through Foundation Medicine's portal and includes a panel of nine genes crucial for oncology drug metabolism.
PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
Foundation Medicine announced the launch of FoundationOne®PGx, a pharmacogenetic (PGx) offering, through an expanded partnership with Fulgent Genetics. This new solution aims to guide cancer therapy selection and dosing strategies by identifying genetic differences that influence drug metabolism. The offering includes a panel of nine genes crucial for oncology drug metabolism, helping healthcare providers anticipate toxicity and improve treatment effectiveness.
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2026 Earnings Call Transcript
Fulgent Genetics (NASDAQ:FLGT) announced its Q1 2026 earnings, reporting a GAAP loss of $0.08 per share and adjusted EBITDA loss of $15.2 million, missing earnings expectations. Despite a revenue decrease to $71.1 million, largely due to a major customer transitioning testing in-house, the company reiterated its full-year 2026 revenue guidance of $350 million. Fulgent Genetics is advancing its therapeutic development pipeline, with FID-007 progressing to Phase III and FID-022 in Phase I, and also highlighted strategic acquisitions and advancements in its laboratory service business.
Fulgent Genetics (FLGT) Trailing US$60 Million Loss Tests Bullish Margin Narratives
Fulgent Genetics (FLGT) reported a US$60.5 million net loss over the last year despite a 10.8% revenue growth. The company's Q1 2026 earnings show continued profitability challenges, with basic EPS at a loss of US$1.97, raising questions for investors about whether current losses are a temporary investment phase or a sustained drag on returns. Analysts do not expect the company to achieve profitability in the near term, challenging the bullish narrative around future margin improvement.
Fulgent Genetics Inc (FLGT) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth Initiatives
Fulgent Genetics Inc (FLGT) reported a decrease in Q1 2026 revenue but highlighted strategic acquisitions of Bako Diagnostics and StrataDx, alongside advancements in its therapeutic pipeline, particularly with FID-007. Despite a GAAP loss and declining gross margins, the company maintains a strong cash position and reiterated its 2026 revenue guidance, focusing on growth in Precision Diagnostics and potential partnerships for its clinical assets.
Fulgent Genetics, Inc. (FLGT) reports Q1 loss, beats revenue estimates
Fulgent Genetics, Inc. (FLGT) announced a Q1 loss, but managed to exceed revenue estimates. The company's financial performance showed a mixed bag, with revenue surprising positively despite the net loss.
Fulgent Genetics Q1 Earnings Call Highlights
Fulgent Genetics reported Q1 revenue of $71.1 million, a decline attributed to a major customer's in-house testing transition and claims processing delays, leading to a GAAP loss of $24.8 million. The company reiterated its full-year 2026 guidance, expecting $350 million in revenue and a non-GAAP loss of $1.59 per share, while actively integrating recent acquisitions and continuing share repurchases. Despite challenges, Fulgent highlighted progress in digital pathology, whole genome testing, and therapeutic development, aiming for reduced customer concentration and improved margins throughout the year.
Full Transcript: Fulgent Genetics Q1 2026 Earnings Call
Fulgent Genetics discussed its Q1 2026 earnings, reporting $71.1 million in revenue, a decrease attributed to a major customer moving testing in-house, but anticipates stabilization and growth later in the year from acquisitions. The company also highlighted advancements in its therapeutic pipeline, with FID007 progressing towards a Phase 3 trial and FID022 in Phase 1, and reiterated its 2026 revenue guidance while adjusting EPS due to stock repurchases. Strategic initiatives including AI integration, new genome tests, and pharmacogenomics were also emphasized.
Fulgent Genetics (NASDAQ:FLGT) Releases FY 2026 Earnings Guidance
Fulgent Genetics (NASDAQ:FLGT) has issued its FY 2026 earnings guidance, projecting an EPS of -$1.59 and revenue of $350.0 million, aligning closely with consensus estimates. The company recently reported Q4 earnings, beating EPS expectations but missing revenue forecasts. FLGT shares currently trade around $15.19, with analysts holding a "Hold" rating and an average target price of $32.00, despite recent downgrades.
Fulgent Genetics (NASDAQ: FLGT) posts Q1 2026 loss, reaffirms $350M revenue outlook
Fulgent Genetics reported a GAAP net loss of $24.8 million for Q1 2026, or $(0.80) per share, on revenues of $71.1 million, down slightly from the previous year. Despite the loss, the company reaffirms its full-year 2026 revenue guidance of $350 million. Fulgent ended the quarter with $604.7 million in cash and repurchased 2.6 million shares for $40.1 million.
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates
Fulgent Genetics (FLGT) reported a Q1 loss of $0.36 per share, missing the Zacks Consensus Estimate of a $0.19 loss, though it beat revenue estimates with $71.14 million. Despite surpassing EPS estimates in three of the last four quarters, the stock has seen a significant decline this year and currently holds a Zacks Rank #4 (Sell), suggesting potential underperformance. Investors are advised to monitor management's upcoming commentary and the industry outlook.
Fulgent Genetics Inc reports results for the quarter ended March 31 - Earnings Summary
Fulgent Genetics Inc (FLGT) has reported its earnings for the quarter ending March 31. The article provides a summary of these results, as reported by Refinitiv.
Fulgent Genetics Inc expected to post a loss of 10 cents a share - Earnings Preview
Fulgent Genetics Inc (FLGT) is anticipated to report a loss of 10 cents per share in its upcoming earnings announcement. This information comes from a Reuters earnings preview. The article highlights key financial expectations for the company.
Fulgent Genetics (FLGT) CFO has 2,747 shares withheld for RSU taxes
Fulgent Genetics' CFO and Treasurer, Paul Kim, had 2,747 shares of common stock withheld on April 26, 2026, to cover tax obligations arising from the vesting of restricted stock units. This was a routine tax-related disposition, not an open-market sale, and the shares were valued at $16.31 each. Following this transaction, Kim continues to hold a substantial 365,800 shares of Fulgent common stock.
Fulgent Genetics (FLGT) COO reports tax-withholding share disposition after RSU vesting
Jian Xie, President and COO of Fulgent Genetics (FLGT), reported a routine tax-related disposition of 4,361 common shares at $16.31 per share. This withholding was to satisfy tax obligations arising from the vesting of restricted stock units (RSUs) assumed through a prior merger. Following this transaction, Xie directly holds 370,952 common shares, with an additional 220,816 shares held indirectly by The Hsieh Family Dynasty Trust.
Fulgent Reports Second Quarter 2024 Financial Results
Fulgent Health (NASDAQ: FLGT) announced its financial results for the second quarter of 2024. The company reported total revenue of $69.5 million and a loss per share of $0.09. Fulgent also provided an updated revenue outlook for the full year 2024, projecting it to be between $270 million and $280 million.
Fulgent Genetics (FLGT) to Release Earnings on Friday
Fulgent Genetics (FLGT) is scheduled to release its Q1 2026 earnings before the market opens on Friday, May 1st. Analysts anticipate an EPS of ($0.3854) and revenue of $68.48 million for the quarter, with FY 2026 guidance set at -1.45 EPS. The company previously topped EPS estimates but reported negative net margin and return on equity, and shares currently trade near $16 with a consensus price target of $32.
Fulgent Genetics rises on earnings, revenue beat
Fulgent Genetics (FLGT) shares increased after the company reported stronger-than-expected earnings and revenue. The positive financial results likely exceeded analyst expectations, leading to a rise in the stock price.
Fulgent Genetics rises on earnings, revenue beat
This article states that Fulgent Genetics (FLGT) shares increased after the company reported an earnings and revenue beat. The specific financial figures or details of the beat are not provided in the snippet.
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
Fulgent Genetics (NASDAQ: FLGT) announced that its abstract, "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)," has been selected for a rapid oral abstract session at the 2026 ASCO Annual Meeting. The presentation will feature interim data from a Phase 2 study evaluating the efficacy and safety of FID-007, an investigational drug, in combination with cetuximab for patients with R/M HNSCC. The company views this as significant progress in addressing a cancer type with limited treatment options.
Fulgent Genetics to present nano-encapsulated anti-tumor drug FID-007 efficacy at ASCO meeting
Fulgent Genetics will present new data on its nano-encapsulated anti-tumor drug, FID-007, at the upcoming American Society of Clinical Oncology (ASCO) meeting. This drug utilizes nano-encapsulation technology to target tumors and is seen as a potential advancement in oncology. The presentation is anticipated to attract significant interest from leading oncology researchers and clinicians.
Head and neck cancer study from Fulgent gets ASCO oral slot
Fulgent Genetics (NASDAQ: FLGT) announced that its abstract on FID-007 in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) has been selected for a rapid oral abstract session at the 2026 ASCO Annual Meeting. The Phase 2 study aims to evaluate the efficacy, pharmacokinetics, and safety of FID-007 in patients with disease progression after PD-L1-based immune checkpoint inhibitor treatment. The company is encouraged by the interim data and believes in FID-007's potential for HNSCC patients with limited treatment options.
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
Lowey Dannenberg, P.C. is investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for potential violations of federal securities laws after the company reported full-year 2025 revenue that fell short of guidance and a sequential decline in fourth-quarter revenue. The firm is encouraging investors who suffered losses to contact their attorneys to discuss participation in the investigation.
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
Lowey Dannenberg, P.C. is investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for potential violations of federal securities laws after the company reported full-year 2025 revenue that fell short of guidance and a sequential decline in fourth-quarter revenue. The firm is encouraging investors who suffered losses in Fulgent securities to contact them regarding the investigation.
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
Lowey Dannenberg P.C. is investigating Fulgent Genetics, Inc. (NASDAQ: FLGT) for potential violations of federal securities laws. This investigation follows Fulgent's disclosure of full-year 2025 revenue that fell short of updated guidance and a sequential decline in fourth-quarter revenue. Investors who suffered losses in Fulgent's securities are encouraged to contact the firm for more information.
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics
Lowey Dannenberg, P.C. is investigating Fulgent Genetics, Inc. (NASDAQ: FLGT) for potential violations of federal securities laws after the company reported disappointing financial results for the fourth quarter and full year 2025. Fulgent's full-year revenue of $322.7 million fell short of updated guidance, and fourth-quarter revenue declined sequentially. Investors who suffered losses in Fulgent securities are encouraged to contact the firm for more information.
